Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on June 9, 2017, reporting events that occurred on June 6, 2017. The filing addresses the departure of two senior executives: Adrian Senderowicz, M.D. (Senior Vice President and Chief Medical Officer) and Scott Eliasof, Ph.D. (Senior Vice President and Chief Scientific Officer).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Adrian Senderowicz, M.D.: Dr. Senderowicz's last day of employment is June 15, 2017. The departure was mutual and did not involve any disagreement with management or the Board.
- Departure of Scott Eliasof, Ph.D.: Dr. Eliasof's last day of employment is June 30, 2017. The departure was mutual and did not involve any disagreement with management or the Board.
- Compensation Implications: Both executives remain eligible for health assistance payments and management change in control bonuses under their existing retention agreements. Neither is required to repay their retention bonus.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or specific risk factors beyond the operational impact of losing two senior officers. Management commentary is limited to confirming the amicable nature of the separations and the terms of the retention agreements.
Investor Verification Checklist
- Verify the impact of losing the Chief Medical Officer and Chief Scientific Officer on the company's clinical trial timelines and drug development pipeline.
- Review the specific terms of the retention agreements referenced in the 2016 Form 10-K/A to understand the exact financial obligations for bonuses and health assistance.
- Confirm whether the company has announced interim replacements or a search process for these critical roles.